{"gene":"CX3CR1","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":1997,"finding":"CX3CR1 was identified as a high-affinity seven-transmembrane G protein-coupled receptor for fractalkine (CX3CL1). It mediates both leukocyte adhesion (independent of pertussis toxin-sensitive G protein signaling and other adhesion molecules, but requiring the chemokine domain atop mucin stalk architecture) and migration (requiring pertussis toxin-sensitive G protein signaling). NK cells predominantly express CX3CR1 and respond to fractalkine in both functions.","method":"Receptor identification by expression cloning; functional adhesion and migration assays; pertussis toxin inhibition experiments","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — original receptor identification with in vitro functional reconstitution, dissection of G protein-dependent vs. independent mechanisms, replicated across multiple cell types","pmids":["9390561"],"is_preprint":false},{"year":1997,"finding":"The orphan G protein-coupled receptor V28 (now known as CX3CR1) shows high sequence similarity to chemokine receptors and can support CD4-independent HIV-2 (ROD/B) entry into feline CCC cells in the presence of sCD4, indicating it can function as an HIV co-receptor.","method":"Transient transfection of CCC cells with V28 followed by HIV-2 infection assay","journal":"Virology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single transfection/infection assay, single lab, no mechanistic follow-up of binding domain","pmids":["9143311"],"is_preprint":false},{"year":2000,"finding":"Hippocampal neurons express CX3CR1, and receptor activation by soluble fractalkine induces Akt phosphorylation and nuclear translocation of NF-κB, protecting neurons from HIV-1 gp120-induced neurotoxicity. Phosphatidylinositol 3-kinase inhibitors blocked both Akt activation and neuroprotection, establishing the PI3K-Akt pathway as the downstream mechanism.","method":"Primary hippocampal neuron cultures, anti-CX3CR1 antibody blocking, PI3K inhibitors, Akt phosphorylation assays, NF-κB nuclear translocation assay, cell viability assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal methods (antibody block, pharmacological inhibition of PI3K, phospholipid activator of Akt) in primary neurons establishing causal pathway","pmids":["10869418"],"is_preprint":false},{"year":2002,"finding":"TGF-β1 increases CX3CR1 mRNA, protein, and 125I-fractalkine binding sites in rat microglia, while blunting fractalkine-stimulated ERK1/2 phosphorylation. The CX3CR1 mRNA half-life was unaltered, and two Smad binding elements were identified in the rat CX3CR1 promoter, suggesting transcriptional upregulation via Smad signaling.","method":"Primary rat microglia cultures, Northern/qPCR, 125I-fractalkine binding assay, ERK1/2 phosphorylation by Western blot, mRNA stability assay, promoter analysis","journal":"Journal of neuroimmunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (binding, signaling, mRNA stability) in primary cells, single lab","pmids":["12446007"],"is_preprint":false},{"year":2003,"finding":"CX3CR1 has three promoters that transcribe three separate exons spliced with a fourth coding exon. Luciferase reporter assays identified positive and negative regulatory elements within these promoters. Mouse CX3CR1 lacks two human promoters and has an additional mouse-specific promoter.","method":"Genomic cloning, promoter-luciferase reporter assays, comparative genomics","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — direct functional promoter assays plus comparative genomic analysis, single lab","pmids":["12551893"],"is_preprint":false},{"year":2003,"finding":"IL-15 specifically inhibits CX3CR1 protein and mRNA accumulation in mouse NK cells (primary bone marrow-derived), whereas IL-2 increases CX3CR1 expression. In vivo injection of IL-15 decreased steady-state CX3CR1 levels in PBMCs, splenocytes, and bone marrow cells; IL-15 treatment also inhibited CX3CL1-induced chemotaxis.","method":"Primary mouse NK cell cultures, in vivo IL-15 injection, flow cytometry, RT-PCR, chemotaxis assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — consistent in vitro and in vivo results with functional readout (chemotaxis), specificity shown by differential regulation vs. IL-2","pmids":["12881312"],"is_preprint":false},{"year":2004,"finding":"IL-15 decreases surface expression of CX3CR1 on human CD56+ NK cells, resulting in diminished CX3CL1-induced chemotaxis and calcium flux. Long-term IL-15 culture abolished CX3CR1 mRNA and protein. The effect was specific: CCR5 mRNA increased while CXCR4 was unchanged.","method":"Human NK cell cultures, flow cytometry, RT-PCR, Western blot, calcium flux assay, chemotaxis assay","journal":"Cellular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (expression, calcium, chemotaxis), single lab, consistent with mouse data in PMID 12881312","pmids":["15598425"],"is_preprint":false},{"year":2008,"finding":"Absence of CX3CR1 or CX3CL1 results in reduced Gr1low (non-classical) blood monocyte levels. CX3CL1 specifically rescues human monocytes from induced cell death, and introduction of a Bcl2 transgene restored wild-type monocyte levels in CX3CR1-deficient mice, establishing that CX3CR1 provides a pro-survival signal to monocytes. Enforced monocyte survival restored atherogenesis in CX3CR1-deficient mice.","method":"CX3CR1 knockout mice, CX3CL1 knockout mice, Bcl2 transgene rescue, in vitro monocyte survival assay with CX3CL1, flow cytometry, atherosclerosis model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (Bcl2 rescue), in vitro survival assay, and in vivo atherogenesis model all converge on same survival mechanism","pmids":["18971423"],"is_preprint":false},{"year":2013,"finding":"CX3CR1 is expressed on pancreatic islet β cells, and CX3CR1 knockout mice exhibit defective glucose- and GLP1-stimulated insulin secretion in vivo and in vitro. FKN treatment of wild-type islets increased intracellular Ca2+ and potentiated insulin secretion in mouse and human islets. KO islets showed reduced expression of genes necessary for differentiated β cell function.","method":"CX3CR1 KO mice, isolated islet insulin secretion assays, in vivo glucose tolerance tests, Ca2+ imaging, gene expression profiling","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — combined in vivo and in vitro approaches, human islet validation, Ca2+ imaging linking receptor activation to secretion, published in high-impact journal","pmids":["23582329"],"is_preprint":false},{"year":2017,"finding":"CX3CR1 directly binds extracellular Tau and triggers its internalization by microglia. Affinity chromatography and competition assays showed Tau competes with CX3CL1 for CX3CR1 binding. Phosphorylation of Tau at S396 reduces its binding affinity for CX3CR1. CX3CR1-deficient mice showed impaired Tau clearance after stereotaxic injection.","method":"Affinity chromatography, CX3CL1-Tau competition binding assay, Cy5-Tau uptake in primary microglia cultures from WT and CX3CR1-/- mice, in vivo stereotaxic Cy5-Tau injection","journal":"Molecular neurodegeneration","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct biochemical binding assay, competition assay, phosphorylation effect on binding, in vitro uptake, and in vivo validation, multiple orthogonal methods","pmids":["28810892"],"is_preprint":false},{"year":2018,"finding":"A missense mutation in CX3CR1 identified in Crohn's disease patients is associated with impaired antifungal responses. CX3CR1+ mononuclear phagocytes express antifungal receptors and activate antifungal responses in a Syk-dependent manner. Genetic ablation of CX3CR1+ MNPs in mice led to changes in gut fungal communities and severe colitis rescued by antifungal treatment.","method":"CX3CR1+ MNP genetic ablation mouse model, Syk inhibition assays, antifungal response assays, microbiome analysis, human genetic association with functional validation","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function with defined phenotypic readout, Syk-dependent mechanism, human mutation with functional validation, antifungal treatment rescue","pmids":["29326275"],"is_preprint":false},{"year":2019,"finding":"CX3CR1 deficiency in microglia impairs NRF2 signaling: mRNA levels of Nrf2 and its target genes were significantly decreased in primary microglia from Cx3cr1-/- mice. CX3CR1-deficient microglia also showed impaired cell migration and phagocytosis, phenocopying NRF2-deficient microglia. Sulforaphane (NRF2 inducer) failed to reduce microgliosis in Cx3cr1-/- mice.","method":"Primary microglia from Cx3cr1-/- mice, RT-PCR for Nrf2 and target genes, migration assays, phagocytosis assays, in vivo sulforaphane treatment in tauopathy model","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays (migration, phagocytosis) with in vivo validation, single lab","pmids":["30769286"],"is_preprint":false},{"year":2019,"finding":"Cx3cr1-deficient microglia from 2-month-old mice exhibit a transcriptomic signature consistent with aged (wild-type) microglia, indicating that CX3CR1 signaling normally restrains a premature aging transcriptome. Loss of Cx3cr1 down-regulates a subset of immune-related genes without substantial epigenetic changes in active chromatin markers.","method":"RNA-sequencing of Cx3cr1-/- vs. WT microglia at multiple ages, ATAC-seq for chromatin accessibility, immunohistochemistry for microglial morphology","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptomics with chromatin profiling and morphological validation, single lab","pmids":["31792059"],"is_preprint":false},{"year":2019,"finding":"CX3CR1 is expressed on tendon-resident macrophage-like cells ('tenophages') together with its ligand CX3CL1. Inhibition of CX3CR1 (fractalkine receptor) blocked tendon cell migration in vitro in 3D tendon-like constructs.","method":"Transgenic reporter mouse models, 3D tendon constructs with CX3CR1 inhibitor, cell migration assay, immunohistochemistry of human tendon","journal":"Disease models & mechanisms","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pharmacological inhibition without genetic confirmation, migration assay only","pmids":["31744815"],"is_preprint":false},{"year":2019,"finding":"CX3CR1+ mononuclear phagocytes expressing LAG-3+ Treg cell-suppressed IL-23 and IL-1β production. The suppression was contact dependent and mediated by LAG-3 engagement of MHC class II on CX3CR1+ macrophages, driving their immunosuppression.","method":"In vivo ILC3-colitis model, conditional depletion of CX3CR1+ macrophages, LAG-3 blocking, contact-dependent suppression assays","journal":"Immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic and functional assays defining a specific contact-dependent mechanism, but CX3CR1 itself is used as a marker/cell identifier rather than the direct mechanistic target","pmids":["30097293"],"is_preprint":false},{"year":2018,"finding":"CX3CR1 deficiency in the homozygous M280 variant impairs CX3CL1-induced monocyte survival. CX3CL1 rescues serum starvation-induced cell death in CX3CR1-WT/WT and heterozygous but not CX3CR1-M280/M280 monocytes. The survival mechanism requires AKT and ERK activation, both of which are impaired in M280/M280 monocytes. CX3CR1-M280/M280 does not affect CX3CR1 surface expression or innate immune effector functions.","method":"Primary monocytes from genotyped human donors (WT, heterozygous, homozygous M280), serum starvation survival assay, AKT/ERK phosphorylation by Western blot, flow cytometry","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — human genetic variant with direct biochemical mechanism (AKT/ERK), negative control (no effect on surface expression), multiple orthogonal methods","pmids":["29415879"],"is_preprint":false},{"year":2022,"finding":"Cryo-electron microscopy structures of CX3CR1-Gi1 complexes in ligand-free and CX3CL1-bound states (2.8 Å and 3.4 Å resolution) revealed key residues governing CX3CL1 recognition. CX3CR1 shows a smaller conformational change in helix VI upon activation than other class A GPCRs, correlated with three cholesterol molecules that play essential roles in conformation stabilization and signaling transduction. Functional assays validated the structural findings.","method":"Cryo-EM structure determination, functional signaling assays, cholesterol interaction analysis","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution cryo-EM structures in two states with orthogonal functional validation, structural mechanism for cholesterol modulation of GPCR activation","pmids":["35767622"],"is_preprint":false},{"year":2019,"finding":"CX3CR1 functions as a receptor for respiratory syncytial virus (RSV) in pediatric airway epithelial cells. RSV preferentially infects CX3CR1-positive cells, and blocking CX3CR1/RSV interaction significantly decreased viral load in primary cultures of differentiated pediatric/infant lung epithelial cells.","method":"In situ hybridization, immunohistochemistry, CX3CR1-blocking experiments in primary pediatric airway epithelial cell cultures, viral load measurement","journal":"Pediatric research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — blocking antibody experiments in physiological primary cell model with viral load readout, corroborated by in vivo cotton rat data (PMID 34037420)","pmids":["31726465"],"is_preprint":false},{"year":2021,"finding":"CX3CR1 functions as a receptor for RSV in vivo in cotton rats. RSV mutants with mutations in the CX3CR1 binding site of the G protein failed to grow in cotton rat lungs, and antibody blocking of the CX3CR1 binding site prevented lung infection. Knockdown of cotton rat CX3CR1 by peptide-conjugated morpholino oligomers led to 10-fold reduction in RSV titers.","method":"Recombinant RSV with G protein mutations, in vivo intranasal infection in cotton rats, CX3CR1 binding-site blocking antibody, peptide-conjugated morpholino knockdown of CX3CR1","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vivo approaches (viral mutant, antibody block, receptor knockdown) all converging on CX3CR1 as RSV receptor","pmids":["34037420"],"is_preprint":false},{"year":2018,"finding":"CX3CR1 deficiency protects against hypoxia-induced pulmonary hypertension. The protective effect occurred with a shift from M2 to M1 macrophage polarization, which diminished conditioned media ability to induce pulmonary artery smooth muscle cell proliferation, partially dependent on CX3CL1 secretion. CX3CR1 inhibitor F1 recapitulated effects of genetic deficiency.","method":"CX3CR1-/- mice in hypoxic PH model, flow cytometry for monocyte/macrophage subsets, macrophage polarization assays, conditioned media PA-SMC proliferation assay, pharmacological CX3CR1 inhibition","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with pharmacological confirmation, mechanistic link through macrophage polarization and CX3CL1-dependent SMC proliferation, single lab","pmids":["28125278"],"is_preprint":false},{"year":2015,"finding":"TGFβ induces CX3CR1 mRNA expression in T cells in a dose- and time-dependent manner. TH17 polarization or TREG cell generation increased CX3CR1 reporter gene expression. Fewer TH17 cells were obtained from CX3CR1-/- splenocytes under polarizing conditions, and CX3CR1 cell-intrinsically promoted aortic T cell accumulation and IL-17 production in atherosclerosis.","method":"Mixed bone marrow chimeras, T cell transfer experiments, TH17/TREG polarization assays, CX3CR1 reporter mice, qPCR for CX3CR1 mRNA","journal":"Journal of the American Society of Nephrology : JASN","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-intrinsic demonstration via chimeric mice plus in vitro polarization assays and TGFβ-dependent induction, single lab","pmids":["26449606"],"is_preprint":false},{"year":2011,"finding":"CX3CR1 expression promotes DC and monocyte/macrophage development under steady-state conditions. Competitive adoptive transfer experiments showed that CX3CR1-deficient precursors had a selective disadvantage in generating DCs and monocytes. Direct intraspleen/intrathymus transfer showed the same competitive advantage, suggesting survival promotion rather than homing is the key mechanism.","method":"Competitive adoptive transfer experiments, direct organ injection of precursors, flow cytometric analysis of DC/monocyte output","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — competitive in vivo transfer with direct-injection controls to distinguish survival vs. homing, single lab","pmids":["21425158"],"is_preprint":false},{"year":2012,"finding":"Fractalkine upregulates inflammation through CX3CR1 and the JAK/STAT signaling pathway in pancreatic acinar cells. FKN and CX3CR1 are overexpressed in cerulein-stimulated AR42J cells. AG490 (JAK inhibitor) and FKN-siRNA inhibited JAK/STAT activation and TNF-α expression in vitro and in a severe acute pancreatitis rat model.","method":"AR42J cell cerulein stimulation, FKN-siRNA knockdown, AG490 JAK inhibitor, Western blot, RT-PCR, ELISA, immunohistochemistry in rat SAP model","journal":"Inflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown combined with pharmacological JAK inhibition and in vivo validation, single lab","pmids":["22213034"],"is_preprint":false},{"year":2017,"finding":"CX3CR1 regulates osteoarthritic chondrocyte proliferation and apoptosis through the Wnt/β-catenin signaling pathway. siRNA knockdown of CX3CR1 in OA chondrocytes activated Wnt/β-catenin (increased nuclear β-catenin, Cyclin D1, MMP-13, phospho-GSK-3β). The Wnt inhibitor XAV-939 abolished the effects of siCX3CR1 on proliferation, apoptosis, and cell cycle.","method":"siRNA knockdown of CX3CR1 in OA chondrocytes, XAV-939 Wnt pathway inhibition, Western blot, MTT proliferation assay, flow cytometry for apoptosis/cell cycle","journal":"Biomedicine & pharmacotherapy","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, siRNA knockdown with pharmacological rescue, no rescue by CX3CR1 re-expression, indirect pathway inference","pmids":["29217163"],"is_preprint":false},{"year":2023,"finding":"CX3CR1 activation by recombinant fractalkine (r-FKN) promotes hematoma resolution and M2 microglial polarization after germinal matrix hemorrhage via the AMPK/PPARγ signaling pathway. CX3CR1 CRISPR knockout or pharmacological CX3CR1 inhibitor (AZD8797) abolished the protective effects of r-FKN. Selective inhibition of microglial AMPK or PPARγ abrogated the anti-inflammatory effects.","method":"Rat GMH model, intranasal r-FKN administration, CX3CR1 CRISPR knockout, AZD8797 pharmacological inhibition, liposome-encapsulated AMPK/PPARγ inhibitors, Western blot, immunofluorescence, hemoglobin assay","journal":"Stroke","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological CX3CR1 manipulation with downstream pathway inhibition, multiple orthogonal approaches, single lab","pmids":["37465997"],"is_preprint":false},{"year":2020,"finding":"CX3CR1 directly interacts with Tau and promotes microglial activation, migration, and proliferation. The CX3CR1/Tau interaction influences internalization of extracellular Tau species by microglia.","method":"Review/synthesis integrating prior experimental data (affinity chromatography binding data from PMID 28810892 and cell biological assays)","journal":"Cell & bioscience","confidence":"Low","confidence_rationale":"Tier 3 / Weak — largely a review that synthesizes previously published experimental data without new primary experiments","pmids":["32944223"],"is_preprint":false},{"year":2022,"finding":"CX3CR1-expressing DRG macrophages contribute to arthritis pain. In vitro, CGRP liberates CX3CR1 ligand fractalkine from endothelium, and FKN promotes activation of intracellular kinases, polarization of bone marrow-derived macrophages toward M1-like phenotype, and release of pro-nociceptive IL-6 via CX3CR1 signaling.","method":"CX3CR1 GFP/GFP knockout mice in K/BxN serum transfer model, in vitro endothelial CGRP stimulation with FKN measurement, BMDM CX3CR1 signaling kinase assays, macrophage polarization and cytokine ELISA","journal":"Brain, behavior, and immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic CX3CR1 KO with in vitro mechanistic pathway dissection, multiple cell types and readouts, single lab","pmids":["36115544"],"is_preprint":false}],"current_model":"CX3CR1 is a seven-transmembrane Gi-coupled chemokine receptor whose cryo-EM structure (with three stabilizing cholesterol molecules) reveals a smaller helix VI conformational change upon CX3CL1 binding than other class A GPCRs; it supports both G protein-independent leukocyte adhesion (requiring the fractalkine chemokine-domain/mucin-stalk architecture) and G protein-dependent chemotaxis, promotes monocyte and NK cell survival via PI3K-AKT and ERK signaling (abrogated by the M280 loss-of-function polymorphism), drives microglial NRF2 signaling and restrains microglial aging, serves as a direct binding receptor for extracellular Tau (with phospho-S396 Tau showing reduced affinity), functions as an entry receptor for RSV in airway epithelium, and modulates β-cell insulin secretion through intracellular Ca²⁺ elevation."},"narrative":{"mechanistic_narrative":"CX3CR1 is a seven-transmembrane G protein-coupled receptor for the chemokine fractalkine (CX3CL1) that couples leukocyte and microglial biology to chemotaxis, adhesion, and cell survival [PMID:9390561]. It mediates two functionally separable outputs: pertussis toxin-independent leukocyte adhesion that requires the chemokine domain presented atop the fractalkine mucin stalk, and pertussis toxin-sensitive, G protein-dependent migration [PMID:9390561]. Cryo-EM structures of the CX3CR1–Gi1 complex in ligand-free and CX3CL1-bound states show a comparatively small helix VI movement upon activation, stabilized by three bound cholesterol molecules essential for conformation and signal transduction [PMID:35767622]. Downstream of CX3CL1, the receptor activates PI3K–AKT and ERK signaling to deliver pro-survival signals: it protects neurons from gp120 neurotoxicity through PI3K–Akt and NF-κB [PMID:10869418], and sustains non-classical monocyte survival—a function abolished by the M280 loss-of-function variant, which impairs AKT/ERK activation without altering surface receptor levels [PMID:18971423, PMID:29415879]. In microglia, CX3CR1 supports NRF2 signaling, migration and phagocytosis and restrains a premature aging transcriptome [PMID:30769286, PMID:31792059], and it serves as a direct binding receptor for extracellular Tau—competing with CX3CL1 and driving microglial Tau internalization, with phospho-S396 Tau binding more weakly [PMID:28810892]. Beyond immune and neural roles, CX3CR1 is expressed on pancreatic β cells where it potentiates glucose-stimulated insulin secretion via intracellular Ca²⁺ [PMID:23582329], and functions as an entry/infection receptor for respiratory syncytial virus in airway epithelium in vitro and in vivo [PMID:31726465, PMID:34037420]. A CX3CR1 missense variant in Crohn's disease patients impairs Syk-dependent antifungal responses of mononuclear phagocytes [PMID:29326275].","teleology":[{"year":1997,"claim":"Established the receptor identity and the dual-output logic of fractalkine signaling, distinguishing G protein-independent adhesion from G protein-dependent migration.","evidence":"expression cloning with adhesion/migration assays and pertussis toxin inhibition across leukocytes including NK cells","pmids":["9390561"],"confidence":"High","gaps":["Structural basis for how the chemokine/mucin architecture drives adhesion was not resolved","In vivo relevance of the two outputs not addressed"]},{"year":1997,"claim":"Tested whether this orphan receptor (V28) could act as a viral co-receptor, broadening its functional range beyond chemotaxis.","evidence":"transient transfection of feline CCC cells supporting CD4-independent HIV-2 entry with sCD4","pmids":["9143311"],"confidence":"Medium","gaps":["Single transfection/infection assay without binding-domain mapping","No follow-up establishing physiological HIV co-receptor role"]},{"year":2000,"claim":"Identified the downstream survival pathway by showing CX3CL1 engages PI3K-Akt and NF-κB to protect neurons.","evidence":"primary hippocampal neurons with antibody block, PI3K inhibition, and Akt/NF-κB readouts under gp120 neurotoxicity","pmids":["10869418"],"confidence":"High","gaps":["Endogenous neuronal CX3CR1 contribution in vivo not defined","Link between Akt and NF-κB activation not mechanistically dissected"]},{"year":2002,"claim":"Defined cytokine control of receptor abundance, showing TGF-β1 transcriptionally upregulates CX3CR1 in microglia via Smad elements.","evidence":"primary rat microglia with binding assays, ERK phosphorylation, mRNA stability, and promoter analysis","pmids":["12446007"],"confidence":"Medium","gaps":["Direct Smad occupancy of the promoter not demonstrated","Functional consequence of blunted ERK signaling unclear"]},{"year":2003,"claim":"Mapped the transcriptional architecture of CX3CR1 (three human promoters/exons) and established mouse-human divergence.","evidence":"genomic cloning, promoter-luciferase reporters, comparative genomics","pmids":["12551893"],"confidence":"Medium","gaps":["Cell-type-specific promoter usage not assigned","Trans-acting factors for the regulatory elements not identified"]},{"year":2003,"claim":"Showed cytokine-specific regulation of NK-cell CX3CR1, with IL-15 suppressing and IL-2 increasing receptor expression and chemotactic function.","evidence":"primary mouse NK cells, in vivo IL-15 injection, RT-PCR, flow cytometry, chemotaxis assays","pmids":["12881312"],"confidence":"High","gaps":["Transcriptional mechanism of IL-15 suppression undefined","Physiological context where IL-15 modulates NK trafficking not established"]},{"year":2004,"claim":"Extended IL-15 regulation to human NK cells, linking surface receptor loss to diminished calcium flux and chemotaxis.","evidence":"human CD56+ NK cells, flow cytometry, calcium flux, and chemotaxis assays with CCR5/CXCR4 specificity controls","pmids":["15598425"],"confidence":"Medium","gaps":["Single lab","Mechanism of selective receptor downregulation not resolved"]},{"year":2008,"claim":"Established that CX3CR1 delivers a pro-survival signal to non-classical monocytes, with downstream consequences for atherogenesis.","evidence":"CX3CR1/CX3CL1 knockout mice, Bcl2 transgene rescue, in vitro survival assays, atherosclerosis model","pmids":["18971423"],"confidence":"High","gaps":["Signaling intermediates linking receptor to survival not detailed here","Whether survival is the sole atherogenic mechanism not excluded"]},{"year":2011,"claim":"Generalized the survival function to DC and monocyte/macrophage development, distinguishing survival promotion from homing.","evidence":"competitive adoptive transfer with direct organ-injection controls and flow cytometry","pmids":["21425158"],"confidence":"Medium","gaps":["Molecular survival pathway in precursors not defined","Ligand source supporting precursor survival unknown"]},{"year":2013,"claim":"Revealed a non-immune endocrine role, showing CX3CR1 potentiates β-cell insulin secretion via intracellular Ca²⁺.","evidence":"CX3CR1 KO mice, isolated mouse and human islet secretion assays, glucose tolerance tests, Ca²⁺ imaging, gene expression profiling","pmids":["23582329"],"confidence":"High","gaps":["Coupling between Ca²⁺ elevation and secretory machinery not detailed","G protein dependence of the islet effect not specified"]},{"year":2017,"claim":"Identified CX3CR1 as a direct extracellular Tau receptor mediating microglial Tau uptake, with phosphorylation modulating affinity.","evidence":"affinity chromatography, CX3CL1-Tau competition binding, microglial uptake assays, in vivo stereotaxic Tau clearance in KO mice","pmids":["28810892"],"confidence":"High","gaps":["Tau binding site on the receptor not mapped","Whether Tau triggers canonical signaling or only internalization unclear"]},{"year":2018,"claim":"Tied a human loss-of-function variant (M280) to defective monocyte survival via impaired AKT/ERK, with surface expression preserved.","evidence":"primary monocytes from genotyped human donors, serum-starvation survival assays, AKT/ERK Western blots, flow cytometry","pmids":["29415879"],"confidence":"High","gaps":["How M280 selectively impairs G protein/kinase coupling not structurally defined","Disease consequences of impaired survival not directly tested here"]},{"year":2018,"claim":"Linked CX3CR1 to vascular disease through macrophage polarization, showing deficiency protects against hypoxic pulmonary hypertension.","evidence":"CX3CR1-/- mice in hypoxic PH model with macrophage polarization, conditioned-media SMC proliferation, and pharmacological inhibition","pmids":["28125278"],"confidence":"Medium","gaps":["Direct receptor signaling driving polarization not isolated","CX3CL1 source in the lung niche not defined"]},{"year":2019,"claim":"Connected CX3CR1 to microglial homeostasis by showing it sustains NRF2 signaling, migration, and phagocytosis.","evidence":"primary Cx3cr1-/- microglia, RT-PCR for Nrf2 targets, migration/phagocytosis assays, in vivo sulforaphane in a tauopathy model","pmids":["30769286"],"confidence":"Medium","gaps":["Mechanistic link from receptor to NRF2 induction unknown","Single lab"]},{"year":2019,"claim":"Showed CX3CR1 normally restrains a premature microglial aging transcriptome without major chromatin remodeling.","evidence":"RNA-seq and ATAC-seq of Cx3cr1-/- vs WT microglia with morphological analysis","pmids":["31792059"],"confidence":"Medium","gaps":["Transcriptional regulators downstream of CX3CR1 not identified","Functional consequence of the aging signature in vivo not tested"]},{"year":2019,"claim":"Identified CX3CR1 as an RSV receptor in human pediatric airway epithelium.","evidence":"in situ hybridization, IHC, and CX3CR1-blocking with viral load readout in primary differentiated airway cultures","pmids":["31726465"],"confidence":"Medium","gaps":["Receptor-virus binding interface not mapped in this study","Antibody blocking alone without genetic confirmation"]},{"year":2021,"claim":"Confirmed CX3CR1 as an RSV receptor in vivo and defined the G-protein CX3CR1 binding site as required for infection.","evidence":"recombinant RSV with G-protein mutations, antibody block, and morpholino knockdown of CX3CR1 in cotton rats","pmids":["34037420"],"confidence":"High","gaps":["Post-attachment entry steps mediated by CX3CR1 not defined","Relevance to human in vivo infection not directly shown"]},{"year":2022,"claim":"Provided the structural mechanism of activation, showing a small helix VI shift stabilized by three cholesterol molecules.","evidence":"cryo-EM of CX3CR1-Gi1 in ligand-free and CX3CL1-bound states with functional validation","pmids":["35767622"],"confidence":"High","gaps":["Structural basis of adhesion vs migration outputs not resolved","How M280 or Tau binding alter the structure not addressed"]},{"year":2018,"claim":"Linked a human CX3CR1 variant to impaired Syk-dependent antifungal immunity and colitis, establishing a Crohn's disease connection.","evidence":"CX3CR1+ MNP genetic ablation in mice, Syk inhibition, microbiome analysis, human genetic association with functional validation","pmids":["29326275"],"confidence":"High","gaps":["Direct CX3CR1 signaling to Syk-coupled antifungal receptors not mapped","Causal chain from receptor variant to fungal dysbiosis incompletely defined"]},{"year":null,"claim":"How a single receptor with a structurally subtle activation mechanism partitions among adhesion, chemotaxis, survival signaling, Tau/viral binding, and Ca²⁺-coupled secretion across diverse cell types remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unified model linking ligand/cholesterol-stabilized conformation to divergent outputs","Binding interfaces for non-chemokine ligands (Tau, RSV G protein) not structurally co-defined","Cell-type-specific effector coupling not systematically mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,16]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[17,18]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,16,15]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,16]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,10,5]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0]}],"complexes":[],"partners":["CX3CL1","GNAI1","MAPT"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P49238","full_name":"CX3C chemokine receptor 1","aliases":["Beta chemokine receptor-like 1","CMK-BRL-1","CMK-BRL1","Fractalkine receptor","G-protein coupled receptor 13","V28"],"length_aa":355,"mass_kda":40.4,"function":"Receptor for the C-X3-C chemokine fractalkine (CX3CL1) present on many early leukocyte cells; CX3CR1-CX3CL1 signaling exerts distinct functions in different tissue compartments, such as immune response, inflammation, cell adhesion and chemotaxis (PubMed:12055230, PubMed:23125415, PubMed:9390561, PubMed:9782118). CX3CR1-CX3CL1 signaling mediates cell migratory functions (By similarity). Responsible for the recruitment of natural killer (NK) cells to inflamed tissues (By similarity). Acts as a regulator of inflammation process leading to atherogenesis by mediating macrophage and monocyte recruitment to inflamed atherosclerotic plaques, promoting cell survival (By similarity). Involved in airway inflammation by promoting interleukin 2-producing T helper (Th2) cell survival in inflamed lung (By similarity). Involved in the migration of circulating monocytes to non-inflamed tissues, where they differentiate into macrophages and dendritic cells (By similarity). Acts as a negative regulator of angiogenesis, probably by promoting macrophage chemotaxis (PubMed:14581400, PubMed:18971423). Plays a key role in brain microglia by regulating inflammatory response in the central nervous system (CNS) and regulating synapse maturation (By similarity). Required to restrain the microglial inflammatory response in the CNS and the resulting parenchymal damage in response to pathological stimuli (By similarity). Involved in brain development by participating in synaptic pruning, a natural process during which brain microglia eliminates extra synapses during postnatal development (By similarity). Synaptic pruning by microglia is required to promote the maturation of circuit connectivity during brain development (By similarity). Acts as an important regulator of the gut microbiota by controlling immunity to intestinal bacteria and fungi (By similarity). Expressed in lamina propria dendritic cells in the small intestine, which form transepithelial dendrites capable of taking up bacteria in order to provide defense against pathogenic bacteria (By similarity). Required to initiate innate and adaptive immune responses against dissemination of commensal fungi (mycobiota) component of the gut: expressed in mononuclear phagocytes (MNPs) and acts by promoting induction of antifungal IgG antibodies response to confer protection against disseminated C.albicans or C.auris infection (PubMed:29326275). Also acts as a receptor for C-C motif chemokine CCL26, inducing cell chemotaxis (PubMed:20974991) (Microbial infection) Acts as a coreceptor with CD4 for HIV-1 virus envelope protein (Microbial infection) Acts as a coreceptor with CD4 for HIV-1 virus envelope protein (PubMed:14607932). May have more potent HIV-1 coreceptothr activity than isoform 1 (PubMed:14607932) (Microbial infection) Acts as a coreceptor with CD4 for HIV-1 virus envelope protein (PubMed:14607932). May have more potent HIV-1 coreceptor activity than isoform 1 (PubMed:14607932)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P49238/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CX3CR1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CX3CR1","total_profiled":1310},"omim":[{"mim_id":"621526","title":"GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE-LIKE PROTEIN; QPCTL","url":"https://www.omim.org/entry/621526"},{"mim_id":"621311","title":"DEVELOPMENTAL DYSPLASIA OF THE HIP 4; DDH4","url":"https://www.omim.org/entry/621311"},{"mim_id":"615612","title":"DEVELOPMENTAL DYSPLASIA OF THE HIP 2; DDH2","url":"https://www.omim.org/entry/615612"},{"mim_id":"613784","title":"MACULAR DEGENERATION, AGE-RELATED, 12; ARMD12","url":"https://www.omim.org/entry/613784"},{"mim_id":"609423","title":"HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/609423"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":33.1}],"url":"https://www.proteinatlas.org/search/CX3CR1"},"hgnc":{"alias_symbol":["CMKDR1","V28","CCRL1"],"prev_symbol":["GPR13","CMKBRL1"]},"alphafold":{"accession":"P49238","domains":[{"cath_id":"1.20.1070.10","chopping":"27-312","consensus_level":"high","plddt":87.0212,"start":27,"end":312}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P49238","model_url":"https://alphafold.ebi.ac.uk/files/AF-P49238-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P49238-F1-predicted_aligned_error_v6.png","plddt_mean":80.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CX3CR1","jax_strain_url":"https://www.jax.org/strain/search?query=CX3CR1"},"sequence":{"accession":"P49238","fasta_url":"https://rest.uniprot.org/uniprotkb/P49238.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P49238/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P49238"}},"corpus_meta":[{"pmid":"9390561","id":"PMC_9390561","title":"Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion.","date":"1997","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9390561","citation_count":1178,"is_preprint":false},{"pmid":"18971423","id":"PMC_18971423","title":"CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18971423","citation_count":396,"is_preprint":false},{"pmid":"10869418","id":"PMC_10869418","title":"Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10869418","citation_count":321,"is_preprint":false},{"pmid":"24352739","id":"PMC_24352739","title":"Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage.","date":"2013","source":"Open biology","url":"https://pubmed.ncbi.nlm.nih.gov/24352739","citation_count":280,"is_preprint":false},{"pmid":"29326275","id":"PMC_29326275","title":"CX3CR1+ mononuclear phagocytes control immunity to intestinal fungi.","date":"2018","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/29326275","citation_count":246,"is_preprint":false},{"pmid":"29361745","id":"PMC_29361745","title":"Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29361745","citation_count":220,"is_preprint":false},{"pmid":"33065974","id":"PMC_33065974","title":"The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33065974","citation_count":212,"is_preprint":false},{"pmid":"25152714","id":"PMC_25152714","title":"Modulating neurotoxicity through CX3CL1/CX3CR1 signaling.","date":"2014","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25152714","citation_count":187,"is_preprint":false},{"pmid":"28810892","id":"PMC_28810892","title":"Absence of CX3CR1 impairs the internalization of Tau by microglia.","date":"2017","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/28810892","citation_count":182,"is_preprint":false},{"pmid":"30097293","id":"PMC_30097293","title":"LAG3+ Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1+ Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis.","date":"2018","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/30097293","citation_count":170,"is_preprint":false},{"pmid":"25987130","id":"PMC_25987130","title":"Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25987130","citation_count":160,"is_preprint":false},{"pmid":"20554025","id":"PMC_20554025","title":"Tickets to the brain: role of CCR2 and CX3CR1 in myeloid cell entry in the CNS.","date":"2010","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/20554025","citation_count":147,"is_preprint":false},{"pmid":"34492237","id":"PMC_34492237","title":"CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases.","date":"2021","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/34492237","citation_count":144,"is_preprint":false},{"pmid":"24847207","id":"PMC_24847207","title":"Fractalkine/CX3CR1 signaling during neuropathic pain.","date":"2014","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24847207","citation_count":133,"is_preprint":false},{"pmid":"9143311","id":"PMC_9143311","title":"CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry.","date":"1997","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/9143311","citation_count":129,"is_preprint":false},{"pmid":"23582329","id":"PMC_23582329","title":"The fractalkine/CX3CR1 system regulates β cell function and insulin secretion.","date":"2013","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/23582329","citation_count":122,"is_preprint":false},{"pmid":"23974513","id":"PMC_23974513","title":"Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway.","date":"2013","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/23974513","citation_count":109,"is_preprint":false},{"pmid":"18424766","id":"PMC_18424766","title":"Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18424766","citation_count":105,"is_preprint":false},{"pmid":"28125278","id":"PMC_28125278","title":"Roles for the CX3CL1/CX3CR1 and CCL2/CCR2 Chemokine Systems in Hypoxic Pulmonary Hypertension.","date":"2017","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28125278","citation_count":99,"is_preprint":false},{"pmid":"31356156","id":"PMC_31356156","title":"Cx3CR1 Expression Identifies Distinct Macrophage Populations That Contribute Differentially to Inflammation and Repair.","date":"2019","source":"ImmunoHorizons","url":"https://pubmed.ncbi.nlm.nih.gov/31356156","citation_count":94,"is_preprint":false},{"pmid":"20055718","id":"PMC_20055718","title":"Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential.","date":"2010","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/20055718","citation_count":93,"is_preprint":false},{"pmid":"12076860","id":"PMC_12076860","title":"Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans.","date":"2002","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/12076860","citation_count":92,"is_preprint":false},{"pmid":"31201215","id":"PMC_31201215","title":"Targeting Microglia Using Cx3cr1-Cre Lines: Revisiting the Specificity.","date":"2019","source":"eNeuro","url":"https://pubmed.ncbi.nlm.nih.gov/31201215","citation_count":91,"is_preprint":false},{"pmid":"12446007","id":"PMC_12446007","title":"TGF-beta1 upregulates CX3CR1 expression and inhibits fractalkine-stimulated signaling in rat microglia.","date":"2002","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/12446007","citation_count":85,"is_preprint":false},{"pmid":"19936834","id":"PMC_19936834","title":"Expression of fractalkine receptor CX3CR1 on cochlear macrophages influences survival of hair cells following ototoxic injury.","date":"2009","source":"Journal of the Association for Research in Otolaryngology : JARO","url":"https://pubmed.ncbi.nlm.nih.gov/19936834","citation_count":85,"is_preprint":false},{"pmid":"12110009","id":"PMC_12110009","title":"Expression of the fractalkine receptor (CX3CR1) in human kidney diseases.","date":"2002","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/12110009","citation_count":83,"is_preprint":false},{"pmid":"32755573","id":"PMC_32755573","title":"Lysophosphatidic Acid-Mediated GPR35 Signaling in CX3CR1+ Macrophages Regulates Intestinal Homeostasis.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32755573","citation_count":82,"is_preprint":false},{"pmid":"20630606","id":"PMC_20630606","title":"Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer.","date":"2010","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/20630606","citation_count":81,"is_preprint":false},{"pmid":"31792059","id":"PMC_31792059","title":"Cx3cr1-deficient microglia exhibit a premature aging transcriptome.","date":"2019","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/31792059","citation_count":78,"is_preprint":false},{"pmid":"32944223","id":"PMC_32944223","title":"Interaction of Tau with the chemokine receptor, CX3CR1 and its effect on microglial activation, migration and proliferation.","date":"2020","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/32944223","citation_count":77,"is_preprint":false},{"pmid":"30948201","id":"PMC_30948201","title":"CX3CL1-CX3CR1 interaction mediates macrophage-mesothelial cross talk and promotes peritoneal fibrosis.","date":"2019","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/30948201","citation_count":75,"is_preprint":false},{"pmid":"7590284","id":"PMC_7590284","title":"The orphan G-protein-coupled receptor-encoding gene V28 is closely related to genes for chemokine receptors and is expressed in lymphoid and neural tissues.","date":"1995","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/7590284","citation_count":74,"is_preprint":false},{"pmid":"24933434","id":"PMC_24933434","title":"Microglia and their CX3CR1 signaling are involved in hippocampal- but not olfactory bulb-related memory and neurogenesis.","date":"2014","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/24933434","citation_count":73,"is_preprint":false},{"pmid":"14533779","id":"PMC_14533779","title":"CX3CL1 and CX3CR1 expression in human brain tissue: noninflammatory control versus multiple sclerosis.","date":"2003","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/14533779","citation_count":70,"is_preprint":false},{"pmid":"15131578","id":"PMC_15131578","title":"Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation.","date":"2004","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15131578","citation_count":69,"is_preprint":false},{"pmid":"15608300","id":"PMC_15608300","title":"Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis.","date":"2005","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/15608300","citation_count":69,"is_preprint":false},{"pmid":"20511186","id":"PMC_20511186","title":"CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-β1.","date":"2010","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20511186","citation_count":68,"is_preprint":false},{"pmid":"21466443","id":"PMC_21466443","title":"Fractalkine/CX3CR1 signalling in chronic pain and inflammation.","date":"2011","source":"Current pharmaceutical biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/21466443","citation_count":66,"is_preprint":false},{"pmid":"15944936","id":"PMC_15944936","title":"Detection of CX3CR1 single nucleotide polymorphism and expression on archived eyes with age-related macular degeneration.","date":"2005","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/15944936","citation_count":64,"is_preprint":false},{"pmid":"17372897","id":"PMC_17372897","title":"Defective antitumor responses in CX3CR1-deficient mice.","date":"2007","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17372897","citation_count":64,"is_preprint":false},{"pmid":"19001328","id":"PMC_19001328","title":"Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma.","date":"2008","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19001328","citation_count":64,"is_preprint":false},{"pmid":"24556958","id":"PMC_24556958","title":"The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: occurrence and potential role in osteoarthritis.","date":"2014","source":"Archivum immunologiae et therapiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/24556958","citation_count":61,"is_preprint":false},{"pmid":"24806473","id":"PMC_24806473","title":"CX3CR1 is a modifying gene of survival and progression in amyotrophic lateral sclerosis.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24806473","citation_count":61,"is_preprint":false},{"pmid":"27429982","id":"PMC_27429982","title":"CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection.","date":"2016","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/27429982","citation_count":59,"is_preprint":false},{"pmid":"30769286","id":"PMC_30769286","title":"CX3CR1-deficient microglia shows impaired signalling of the transcription factor NRF2: Implications in tauopathies.","date":"2019","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/30769286","citation_count":59,"is_preprint":false},{"pmid":"32369455","id":"PMC_32369455","title":"Inflammescent CX3CR1+CD57+CD8+ T cells are generated and expanded by IL-15.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32369455","citation_count":53,"is_preprint":false},{"pmid":"26765996","id":"PMC_26765996","title":"Up-regulated fractalkine (FKN) and its receptor CX3CR1 are involved in fructose-induced neuroinflammation: Suppression by curcumin.","date":"2016","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/26765996","citation_count":52,"is_preprint":false},{"pmid":"26285829","id":"PMC_26285829","title":"CX3CR1 is dysregulated in blood and brain from schizophrenia patients.","date":"2015","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/26285829","citation_count":51,"is_preprint":false},{"pmid":"30843484","id":"PMC_30843484","title":"Crosstalk between the CX3CL1/CX3CR1 Axis and Inflammatory Signaling Pathways in Tissue Injury.","date":"2019","source":"Current protein & peptide science","url":"https://pubmed.ncbi.nlm.nih.gov/30843484","citation_count":51,"is_preprint":false},{"pmid":"25502213","id":"PMC_25502213","title":"Differential expression of the fractalkine chemokine receptor (CX3CR1) in human monocytes during differentiation.","date":"2014","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25502213","citation_count":51,"is_preprint":false},{"pmid":"32400390","id":"PMC_32400390","title":"Dissecting the phenotypic and functional heterogeneity of mouse inflammatory osteoclasts by the expression of Cx3cr1.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/32400390","citation_count":51,"is_preprint":false},{"pmid":"31726465","id":"PMC_31726465","title":"CX3CR1 as a respiratory syncytial virus receptor in pediatric human lung.","date":"2019","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/31726465","citation_count":49,"is_preprint":false},{"pmid":"29259682","id":"PMC_29259682","title":"Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway.","date":"2016","source":"Inflammation and regeneration","url":"https://pubmed.ncbi.nlm.nih.gov/29259682","citation_count":48,"is_preprint":false},{"pmid":"21451526","id":"PMC_21451526","title":"Fractalkine and its receptor, CX3CR1, promote hypertensive interstitial fibrosis in the kidney.","date":"2011","source":"Hypertension research : official journal of the Japanese Society of Hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/21451526","citation_count":47,"is_preprint":false},{"pmid":"35767622","id":"PMC_35767622","title":"Activation of the human chemokine receptor CX3CR1 regulated by cholesterol.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35767622","citation_count":46,"is_preprint":false},{"pmid":"29446734","id":"PMC_29446734","title":"CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?","date":"2017","source":"Current gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29446734","citation_count":44,"is_preprint":false},{"pmid":"31744815","id":"PMC_31744815","title":"Tenophages: a novel macrophage-like tendon cell population expressing CX3CL1 and CX3CR1.","date":"2019","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/31744815","citation_count":44,"is_preprint":false},{"pmid":"12028445","id":"PMC_12028445","title":"Fractalkine expression and the recruitment of CX3CR1+ cells in the prolonged mesangial proliferative glomerulonephritis.","date":"2002","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/12028445","citation_count":44,"is_preprint":false},{"pmid":"29669747","id":"PMC_29669747","title":"The Role of the Microglial Cx3cr1 Pathway in the Postnatal Maturation of Retinal Photoreceptors.","date":"2018","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29669747","citation_count":44,"is_preprint":false},{"pmid":"34009468","id":"PMC_34009468","title":"Regulation and function of CX3CR1 and its ligand CX3CL1 in kidney disease.","date":"2021","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/34009468","citation_count":42,"is_preprint":false},{"pmid":"32582197","id":"PMC_32582197","title":"Revising CX3CR1 Expression on Murine Classical and Non-classical Monocytes.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32582197","citation_count":42,"is_preprint":false},{"pmid":"23956503","id":"PMC_23956503","title":"Fractalkine (CX3CL1) and its receptor CX3CR1 may contribute to increased angiogenesis in diabetic placenta.","date":"2013","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/23956503","citation_count":42,"is_preprint":false},{"pmid":"23232206","id":"PMC_23232206","title":"Ccl2, Cx3cr1 and Ccl2/Cx3cr1 chemokine deficiencies are not sufficient to cause age-related retinal degeneration.","date":"2012","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/23232206","citation_count":41,"is_preprint":false},{"pmid":"38731899","id":"PMC_38731899","title":"CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38731899","citation_count":40,"is_preprint":false},{"pmid":"15153757","id":"PMC_15153757","title":"Fractalkine and its receptor, CX3CR1, upregulation in streptozotocin-induced diabetic kidneys.","date":"2004","source":"Nephron. Experimental nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/15153757","citation_count":40,"is_preprint":false},{"pmid":"32236410","id":"PMC_32236410","title":"Role of CX3CR1 signaling in malignant transformation of gliomas.","date":"2020","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32236410","citation_count":39,"is_preprint":false},{"pmid":"32662924","id":"PMC_32662924","title":"Microglial CX3CR1 production increases in Alzheimer's disease and is regulated by noradrenaline.","date":"2020","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/32662924","citation_count":39,"is_preprint":false},{"pmid":"35140706","id":"PMC_35140706","title":"CX3CR1 Acts as a Protective Biomarker in the Tumor Microenvironment of Colorectal Cancer.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35140706","citation_count":39,"is_preprint":false},{"pmid":"28450294","id":"PMC_28450294","title":"Gas6 Promotes Inflammatory (CCR2hiCX3CR1lo) Monocyte Recruitment in Venous Thrombosis.","date":"2017","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28450294","citation_count":39,"is_preprint":false},{"pmid":"36644710","id":"PMC_36644710","title":"Fractalkine/CX3CR1-Dependent Modulation of Synaptic and Network Plasticity in Health and Disease.","date":"2023","source":"Neural plasticity","url":"https://pubmed.ncbi.nlm.nih.gov/36644710","citation_count":38,"is_preprint":false},{"pmid":"12881312","id":"PMC_12881312","title":"IL-15 and IL-2 oppositely regulate expression of the chemokine receptor CX3CR1.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12881312","citation_count":37,"is_preprint":false},{"pmid":"36115544","id":"PMC_36115544","title":"Dorsal root ganglia CX3CR1 expressing monocytes/macrophages contribute to arthritis pain.","date":"2022","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/36115544","citation_count":35,"is_preprint":false},{"pmid":"37465997","id":"PMC_37465997","title":"Fractalkine Enhances Hematoma Resolution and Improves Neurological Function via CX3CR1/AMPK/PPARγ Pathway After GMH.","date":"2023","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/37465997","citation_count":33,"is_preprint":false},{"pmid":"28800592","id":"PMC_28800592","title":"CX3CR1 knockout aggravates Coxsackievirus B3-induced myocarditis.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28800592","citation_count":33,"is_preprint":false},{"pmid":"17082760","id":"PMC_17082760","title":"Association study between the CX3CR1 gene and asthma.","date":"2006","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/17082760","citation_count":33,"is_preprint":false},{"pmid":"25503251","id":"PMC_25503251","title":"CX3CL1/CX3CR1 and CCL2/CCR2 chemokine/chemokine receptor complex in patients with AMD.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25503251","citation_count":31,"is_preprint":false},{"pmid":"33582183","id":"PMC_33582183","title":"Dynamic role of macrophage CX3CR1 expression in inflammatory bowel disease.","date":"2021","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33582183","citation_count":30,"is_preprint":false},{"pmid":"26458944","id":"PMC_26458944","title":"Expression pattern of Ccr2 and Cx3cr1 in inherited retinal degeneration.","date":"2015","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/26458944","citation_count":29,"is_preprint":false},{"pmid":"31780870","id":"PMC_31780870","title":"Role of CX3CL1/CX3CR1 Signaling Axis Activity in Osteoporosis.","date":"2019","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/31780870","citation_count":29,"is_preprint":false},{"pmid":"26449606","id":"PMC_26449606","title":"T Cell CX3CR1 Mediates Excess Atherosclerotic Inflammation in Renal Impairment.","date":"2015","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/26449606","citation_count":29,"is_preprint":false},{"pmid":"26393344","id":"PMC_26393344","title":"Metabolic Effects of CX3CR1 Deficiency in Diet-Induced Obese Mice.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26393344","citation_count":29,"is_preprint":false},{"pmid":"20004358","id":"PMC_20004358","title":"Relevance of the CX3CL1/fractalkine-CX3CR1 pathway in vasculitis and vasculopathy.","date":"2010","source":"Translational research : the journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20004358","citation_count":29,"is_preprint":false},{"pmid":"22213034","id":"PMC_22213034","title":"Fractalkine upregulates inflammation through CX3CR1 and the Jak-Stat pathway in severe acute pancreatitis rat model.","date":"2012","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/22213034","citation_count":29,"is_preprint":false},{"pmid":"35770395","id":"PMC_35770395","title":"Structure and Function of Ligand CX3CL1 and its Receptor CX3CR1 in Cancer.","date":"2022","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35770395","citation_count":28,"is_preprint":false},{"pmid":"26038823","id":"PMC_26038823","title":"Neuronal Cx3cr1 Deficiency Protects against Amyloid β-Induced Neurotoxicity.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26038823","citation_count":28,"is_preprint":false},{"pmid":"18296082","id":"PMC_18296082","title":"Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease.","date":"2008","source":"European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/18296082","citation_count":28,"is_preprint":false},{"pmid":"21425158","id":"PMC_21425158","title":"Chemokine receptor CX3CR1 promotes dendritic cell development under steady-state conditions.","date":"2011","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21425158","citation_count":28,"is_preprint":false},{"pmid":"15598425","id":"PMC_15598425","title":"IL-15 alters expression and function of the chemokine receptor CX3CR1 in human NK cells.","date":"2004","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15598425","citation_count":27,"is_preprint":false},{"pmid":"28844811","id":"PMC_28844811","title":"The Multifaceted Personality of Intestinal CX3CR1+ Macrophages.","date":"2017","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28844811","citation_count":27,"is_preprint":false},{"pmid":"29415879","id":"PMC_29415879","title":"The homozygous CX3CR1-M280 mutation impairs human monocyte survival.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/29415879","citation_count":26,"is_preprint":false},{"pmid":"34037420","id":"PMC_34037420","title":"CX3CR1 Is a Receptor for Human Respiratory Syncytial Virus in Cotton Rats.","date":"2021","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/34037420","citation_count":26,"is_preprint":false},{"pmid":"25845619","id":"PMC_25845619","title":"Chemokine CX3CL1 and its receptor CX3CR1 are associated with human atherosclerotic lesion volnerability.","date":"2015","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/25845619","citation_count":26,"is_preprint":false},{"pmid":"29217163","id":"PMC_29217163","title":"CX3CR1 regulates osteoarthrosis chondrocyte proliferation and apoptosis via Wnt/β-catenin signaling.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/29217163","citation_count":25,"is_preprint":false},{"pmid":"39710592","id":"PMC_39710592","title":"Fusobacterium nucleatum-driven CX3CR1+ PD-L1+ phagocytes route to tumor tissues and reshape tumor microenvironment.","date":"2024","source":"Gut microbes","url":"https://pubmed.ncbi.nlm.nih.gov/39710592","citation_count":24,"is_preprint":false},{"pmid":"37771579","id":"PMC_37771579","title":"The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37771579","citation_count":24,"is_preprint":false},{"pmid":"33641164","id":"PMC_33641164","title":"Potential biomarkers reflecting inflammation in patients with severe periodontitis: Fractalkine (CX3CL1) and its receptor (CX3CR1).","date":"2021","source":"Journal of periodontal research","url":"https://pubmed.ncbi.nlm.nih.gov/33641164","citation_count":24,"is_preprint":false},{"pmid":"24084767","id":"PMC_24084767","title":"Early expression of the fractalkine receptor CX3CR1 in pancreatic carcinogenesis.","date":"2013","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24084767","citation_count":23,"is_preprint":false},{"pmid":"28978662","id":"PMC_28978662","title":"Fractalkine induces angiogenic potential in CX3CR1-expressing monocytes.","date":"2017","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/28978662","citation_count":23,"is_preprint":false},{"pmid":"34037810","id":"PMC_34037810","title":"CD40 and CD80/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1+ CD8+ T cells.","date":"2021","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/34037810","citation_count":23,"is_preprint":false},{"pmid":"12551893","id":"PMC_12551893","title":"Genomic organization and evolution of the CX3CR1/CCR8 chemokine receptor locus.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12551893","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51777,"output_tokens":7206,"usd":0.131711,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16454,"output_tokens":5177,"usd":0.105847,"stage2_stop_reason":"end_turn"},"total_usd":0.237558,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"CX3CR1 was identified as a high-affinity seven-transmembrane G protein-coupled receptor for fractalkine (CX3CL1). It mediates both leukocyte adhesion (independent of pertussis toxin-sensitive G protein signaling and other adhesion molecules, but requiring the chemokine domain atop mucin stalk architecture) and migration (requiring pertussis toxin-sensitive G protein signaling). NK cells predominantly express CX3CR1 and respond to fractalkine in both functions.\",\n      \"method\": \"Receptor identification by expression cloning; functional adhesion and migration assays; pertussis toxin inhibition experiments\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — original receptor identification with in vitro functional reconstitution, dissection of G protein-dependent vs. independent mechanisms, replicated across multiple cell types\",\n      \"pmids\": [\"9390561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The orphan G protein-coupled receptor V28 (now known as CX3CR1) shows high sequence similarity to chemokine receptors and can support CD4-independent HIV-2 (ROD/B) entry into feline CCC cells in the presence of sCD4, indicating it can function as an HIV co-receptor.\",\n      \"method\": \"Transient transfection of CCC cells with V28 followed by HIV-2 infection assay\",\n      \"journal\": \"Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single transfection/infection assay, single lab, no mechanistic follow-up of binding domain\",\n      \"pmids\": [\"9143311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Hippocampal neurons express CX3CR1, and receptor activation by soluble fractalkine induces Akt phosphorylation and nuclear translocation of NF-κB, protecting neurons from HIV-1 gp120-induced neurotoxicity. Phosphatidylinositol 3-kinase inhibitors blocked both Akt activation and neuroprotection, establishing the PI3K-Akt pathway as the downstream mechanism.\",\n      \"method\": \"Primary hippocampal neuron cultures, anti-CX3CR1 antibody blocking, PI3K inhibitors, Akt phosphorylation assays, NF-κB nuclear translocation assay, cell viability assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal methods (antibody block, pharmacological inhibition of PI3K, phospholipid activator of Akt) in primary neurons establishing causal pathway\",\n      \"pmids\": [\"10869418\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TGF-β1 increases CX3CR1 mRNA, protein, and 125I-fractalkine binding sites in rat microglia, while blunting fractalkine-stimulated ERK1/2 phosphorylation. The CX3CR1 mRNA half-life was unaltered, and two Smad binding elements were identified in the rat CX3CR1 promoter, suggesting transcriptional upregulation via Smad signaling.\",\n      \"method\": \"Primary rat microglia cultures, Northern/qPCR, 125I-fractalkine binding assay, ERK1/2 phosphorylation by Western blot, mRNA stability assay, promoter analysis\",\n      \"journal\": \"Journal of neuroimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (binding, signaling, mRNA stability) in primary cells, single lab\",\n      \"pmids\": [\"12446007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CX3CR1 has three promoters that transcribe three separate exons spliced with a fourth coding exon. Luciferase reporter assays identified positive and negative regulatory elements within these promoters. Mouse CX3CR1 lacks two human promoters and has an additional mouse-specific promoter.\",\n      \"method\": \"Genomic cloning, promoter-luciferase reporter assays, comparative genomics\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct functional promoter assays plus comparative genomic analysis, single lab\",\n      \"pmids\": [\"12551893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"IL-15 specifically inhibits CX3CR1 protein and mRNA accumulation in mouse NK cells (primary bone marrow-derived), whereas IL-2 increases CX3CR1 expression. In vivo injection of IL-15 decreased steady-state CX3CR1 levels in PBMCs, splenocytes, and bone marrow cells; IL-15 treatment also inhibited CX3CL1-induced chemotaxis.\",\n      \"method\": \"Primary mouse NK cell cultures, in vivo IL-15 injection, flow cytometry, RT-PCR, chemotaxis assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — consistent in vitro and in vivo results with functional readout (chemotaxis), specificity shown by differential regulation vs. IL-2\",\n      \"pmids\": [\"12881312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-15 decreases surface expression of CX3CR1 on human CD56+ NK cells, resulting in diminished CX3CL1-induced chemotaxis and calcium flux. Long-term IL-15 culture abolished CX3CR1 mRNA and protein. The effect was specific: CCR5 mRNA increased while CXCR4 was unchanged.\",\n      \"method\": \"Human NK cell cultures, flow cytometry, RT-PCR, Western blot, calcium flux assay, chemotaxis assay\",\n      \"journal\": \"Cellular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (expression, calcium, chemotaxis), single lab, consistent with mouse data in PMID 12881312\",\n      \"pmids\": [\"15598425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Absence of CX3CR1 or CX3CL1 results in reduced Gr1low (non-classical) blood monocyte levels. CX3CL1 specifically rescues human monocytes from induced cell death, and introduction of a Bcl2 transgene restored wild-type monocyte levels in CX3CR1-deficient mice, establishing that CX3CR1 provides a pro-survival signal to monocytes. Enforced monocyte survival restored atherogenesis in CX3CR1-deficient mice.\",\n      \"method\": \"CX3CR1 knockout mice, CX3CL1 knockout mice, Bcl2 transgene rescue, in vitro monocyte survival assay with CX3CL1, flow cytometry, atherosclerosis model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (Bcl2 rescue), in vitro survival assay, and in vivo atherogenesis model all converge on same survival mechanism\",\n      \"pmids\": [\"18971423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CX3CR1 is expressed on pancreatic islet β cells, and CX3CR1 knockout mice exhibit defective glucose- and GLP1-stimulated insulin secretion in vivo and in vitro. FKN treatment of wild-type islets increased intracellular Ca2+ and potentiated insulin secretion in mouse and human islets. KO islets showed reduced expression of genes necessary for differentiated β cell function.\",\n      \"method\": \"CX3CR1 KO mice, isolated islet insulin secretion assays, in vivo glucose tolerance tests, Ca2+ imaging, gene expression profiling\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — combined in vivo and in vitro approaches, human islet validation, Ca2+ imaging linking receptor activation to secretion, published in high-impact journal\",\n      \"pmids\": [\"23582329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CX3CR1 directly binds extracellular Tau and triggers its internalization by microglia. Affinity chromatography and competition assays showed Tau competes with CX3CL1 for CX3CR1 binding. Phosphorylation of Tau at S396 reduces its binding affinity for CX3CR1. CX3CR1-deficient mice showed impaired Tau clearance after stereotaxic injection.\",\n      \"method\": \"Affinity chromatography, CX3CL1-Tau competition binding assay, Cy5-Tau uptake in primary microglia cultures from WT and CX3CR1-/- mice, in vivo stereotaxic Cy5-Tau injection\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct biochemical binding assay, competition assay, phosphorylation effect on binding, in vitro uptake, and in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"28810892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A missense mutation in CX3CR1 identified in Crohn's disease patients is associated with impaired antifungal responses. CX3CR1+ mononuclear phagocytes express antifungal receptors and activate antifungal responses in a Syk-dependent manner. Genetic ablation of CX3CR1+ MNPs in mice led to changes in gut fungal communities and severe colitis rescued by antifungal treatment.\",\n      \"method\": \"CX3CR1+ MNP genetic ablation mouse model, Syk inhibition assays, antifungal response assays, microbiome analysis, human genetic association with functional validation\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function with defined phenotypic readout, Syk-dependent mechanism, human mutation with functional validation, antifungal treatment rescue\",\n      \"pmids\": [\"29326275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CX3CR1 deficiency in microglia impairs NRF2 signaling: mRNA levels of Nrf2 and its target genes were significantly decreased in primary microglia from Cx3cr1-/- mice. CX3CR1-deficient microglia also showed impaired cell migration and phagocytosis, phenocopying NRF2-deficient microglia. Sulforaphane (NRF2 inducer) failed to reduce microgliosis in Cx3cr1-/- mice.\",\n      \"method\": \"Primary microglia from Cx3cr1-/- mice, RT-PCR for Nrf2 and target genes, migration assays, phagocytosis assays, in vivo sulforaphane treatment in tauopathy model\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays (migration, phagocytosis) with in vivo validation, single lab\",\n      \"pmids\": [\"30769286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cx3cr1-deficient microglia from 2-month-old mice exhibit a transcriptomic signature consistent with aged (wild-type) microglia, indicating that CX3CR1 signaling normally restrains a premature aging transcriptome. Loss of Cx3cr1 down-regulates a subset of immune-related genes without substantial epigenetic changes in active chromatin markers.\",\n      \"method\": \"RNA-sequencing of Cx3cr1-/- vs. WT microglia at multiple ages, ATAC-seq for chromatin accessibility, immunohistochemistry for microglial morphology\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptomics with chromatin profiling and morphological validation, single lab\",\n      \"pmids\": [\"31792059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CX3CR1 is expressed on tendon-resident macrophage-like cells ('tenophages') together with its ligand CX3CL1. Inhibition of CX3CR1 (fractalkine receptor) blocked tendon cell migration in vitro in 3D tendon-like constructs.\",\n      \"method\": \"Transgenic reporter mouse models, 3D tendon constructs with CX3CR1 inhibitor, cell migration assay, immunohistochemistry of human tendon\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pharmacological inhibition without genetic confirmation, migration assay only\",\n      \"pmids\": [\"31744815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CX3CR1+ mononuclear phagocytes expressing LAG-3+ Treg cell-suppressed IL-23 and IL-1β production. The suppression was contact dependent and mediated by LAG-3 engagement of MHC class II on CX3CR1+ macrophages, driving their immunosuppression.\",\n      \"method\": \"In vivo ILC3-colitis model, conditional depletion of CX3CR1+ macrophages, LAG-3 blocking, contact-dependent suppression assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic and functional assays defining a specific contact-dependent mechanism, but CX3CR1 itself is used as a marker/cell identifier rather than the direct mechanistic target\",\n      \"pmids\": [\"30097293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CX3CR1 deficiency in the homozygous M280 variant impairs CX3CL1-induced monocyte survival. CX3CL1 rescues serum starvation-induced cell death in CX3CR1-WT/WT and heterozygous but not CX3CR1-M280/M280 monocytes. The survival mechanism requires AKT and ERK activation, both of which are impaired in M280/M280 monocytes. CX3CR1-M280/M280 does not affect CX3CR1 surface expression or innate immune effector functions.\",\n      \"method\": \"Primary monocytes from genotyped human donors (WT, heterozygous, homozygous M280), serum starvation survival assay, AKT/ERK phosphorylation by Western blot, flow cytometry\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — human genetic variant with direct biochemical mechanism (AKT/ERK), negative control (no effect on surface expression), multiple orthogonal methods\",\n      \"pmids\": [\"29415879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cryo-electron microscopy structures of CX3CR1-Gi1 complexes in ligand-free and CX3CL1-bound states (2.8 Å and 3.4 Å resolution) revealed key residues governing CX3CL1 recognition. CX3CR1 shows a smaller conformational change in helix VI upon activation than other class A GPCRs, correlated with three cholesterol molecules that play essential roles in conformation stabilization and signaling transduction. Functional assays validated the structural findings.\",\n      \"method\": \"Cryo-EM structure determination, functional signaling assays, cholesterol interaction analysis\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution cryo-EM structures in two states with orthogonal functional validation, structural mechanism for cholesterol modulation of GPCR activation\",\n      \"pmids\": [\"35767622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CX3CR1 functions as a receptor for respiratory syncytial virus (RSV) in pediatric airway epithelial cells. RSV preferentially infects CX3CR1-positive cells, and blocking CX3CR1/RSV interaction significantly decreased viral load in primary cultures of differentiated pediatric/infant lung epithelial cells.\",\n      \"method\": \"In situ hybridization, immunohistochemistry, CX3CR1-blocking experiments in primary pediatric airway epithelial cell cultures, viral load measurement\",\n      \"journal\": \"Pediatric research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — blocking antibody experiments in physiological primary cell model with viral load readout, corroborated by in vivo cotton rat data (PMID 34037420)\",\n      \"pmids\": [\"31726465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CX3CR1 functions as a receptor for RSV in vivo in cotton rats. RSV mutants with mutations in the CX3CR1 binding site of the G protein failed to grow in cotton rat lungs, and antibody blocking of the CX3CR1 binding site prevented lung infection. Knockdown of cotton rat CX3CR1 by peptide-conjugated morpholino oligomers led to 10-fold reduction in RSV titers.\",\n      \"method\": \"Recombinant RSV with G protein mutations, in vivo intranasal infection in cotton rats, CX3CR1 binding-site blocking antibody, peptide-conjugated morpholino knockdown of CX3CR1\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vivo approaches (viral mutant, antibody block, receptor knockdown) all converging on CX3CR1 as RSV receptor\",\n      \"pmids\": [\"34037420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CX3CR1 deficiency protects against hypoxia-induced pulmonary hypertension. The protective effect occurred with a shift from M2 to M1 macrophage polarization, which diminished conditioned media ability to induce pulmonary artery smooth muscle cell proliferation, partially dependent on CX3CL1 secretion. CX3CR1 inhibitor F1 recapitulated effects of genetic deficiency.\",\n      \"method\": \"CX3CR1-/- mice in hypoxic PH model, flow cytometry for monocyte/macrophage subsets, macrophage polarization assays, conditioned media PA-SMC proliferation assay, pharmacological CX3CR1 inhibition\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with pharmacological confirmation, mechanistic link through macrophage polarization and CX3CL1-dependent SMC proliferation, single lab\",\n      \"pmids\": [\"28125278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TGFβ induces CX3CR1 mRNA expression in T cells in a dose- and time-dependent manner. TH17 polarization or TREG cell generation increased CX3CR1 reporter gene expression. Fewer TH17 cells were obtained from CX3CR1-/- splenocytes under polarizing conditions, and CX3CR1 cell-intrinsically promoted aortic T cell accumulation and IL-17 production in atherosclerosis.\",\n      \"method\": \"Mixed bone marrow chimeras, T cell transfer experiments, TH17/TREG polarization assays, CX3CR1 reporter mice, qPCR for CX3CR1 mRNA\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-intrinsic demonstration via chimeric mice plus in vitro polarization assays and TGFβ-dependent induction, single lab\",\n      \"pmids\": [\"26449606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CX3CR1 expression promotes DC and monocyte/macrophage development under steady-state conditions. Competitive adoptive transfer experiments showed that CX3CR1-deficient precursors had a selective disadvantage in generating DCs and monocytes. Direct intraspleen/intrathymus transfer showed the same competitive advantage, suggesting survival promotion rather than homing is the key mechanism.\",\n      \"method\": \"Competitive adoptive transfer experiments, direct organ injection of precursors, flow cytometric analysis of DC/monocyte output\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — competitive in vivo transfer with direct-injection controls to distinguish survival vs. homing, single lab\",\n      \"pmids\": [\"21425158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Fractalkine upregulates inflammation through CX3CR1 and the JAK/STAT signaling pathway in pancreatic acinar cells. FKN and CX3CR1 are overexpressed in cerulein-stimulated AR42J cells. AG490 (JAK inhibitor) and FKN-siRNA inhibited JAK/STAT activation and TNF-α expression in vitro and in a severe acute pancreatitis rat model.\",\n      \"method\": \"AR42J cell cerulein stimulation, FKN-siRNA knockdown, AG490 JAK inhibitor, Western blot, RT-PCR, ELISA, immunohistochemistry in rat SAP model\",\n      \"journal\": \"Inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown combined with pharmacological JAK inhibition and in vivo validation, single lab\",\n      \"pmids\": [\"22213034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CX3CR1 regulates osteoarthritic chondrocyte proliferation and apoptosis through the Wnt/β-catenin signaling pathway. siRNA knockdown of CX3CR1 in OA chondrocytes activated Wnt/β-catenin (increased nuclear β-catenin, Cyclin D1, MMP-13, phospho-GSK-3β). The Wnt inhibitor XAV-939 abolished the effects of siCX3CR1 on proliferation, apoptosis, and cell cycle.\",\n      \"method\": \"siRNA knockdown of CX3CR1 in OA chondrocytes, XAV-939 Wnt pathway inhibition, Western blot, MTT proliferation assay, flow cytometry for apoptosis/cell cycle\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, siRNA knockdown with pharmacological rescue, no rescue by CX3CR1 re-expression, indirect pathway inference\",\n      \"pmids\": [\"29217163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CX3CR1 activation by recombinant fractalkine (r-FKN) promotes hematoma resolution and M2 microglial polarization after germinal matrix hemorrhage via the AMPK/PPARγ signaling pathway. CX3CR1 CRISPR knockout or pharmacological CX3CR1 inhibitor (AZD8797) abolished the protective effects of r-FKN. Selective inhibition of microglial AMPK or PPARγ abrogated the anti-inflammatory effects.\",\n      \"method\": \"Rat GMH model, intranasal r-FKN administration, CX3CR1 CRISPR knockout, AZD8797 pharmacological inhibition, liposome-encapsulated AMPK/PPARγ inhibitors, Western blot, immunofluorescence, hemoglobin assay\",\n      \"journal\": \"Stroke\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological CX3CR1 manipulation with downstream pathway inhibition, multiple orthogonal approaches, single lab\",\n      \"pmids\": [\"37465997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CX3CR1 directly interacts with Tau and promotes microglial activation, migration, and proliferation. The CX3CR1/Tau interaction influences internalization of extracellular Tau species by microglia.\",\n      \"method\": \"Review/synthesis integrating prior experimental data (affinity chromatography binding data from PMID 28810892 and cell biological assays)\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — largely a review that synthesizes previously published experimental data without new primary experiments\",\n      \"pmids\": [\"32944223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CX3CR1-expressing DRG macrophages contribute to arthritis pain. In vitro, CGRP liberates CX3CR1 ligand fractalkine from endothelium, and FKN promotes activation of intracellular kinases, polarization of bone marrow-derived macrophages toward M1-like phenotype, and release of pro-nociceptive IL-6 via CX3CR1 signaling.\",\n      \"method\": \"CX3CR1 GFP/GFP knockout mice in K/BxN serum transfer model, in vitro endothelial CGRP stimulation with FKN measurement, BMDM CX3CR1 signaling kinase assays, macrophage polarization and cytokine ELISA\",\n      \"journal\": \"Brain, behavior, and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic CX3CR1 KO with in vitro mechanistic pathway dissection, multiple cell types and readouts, single lab\",\n      \"pmids\": [\"36115544\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CX3CR1 is a seven-transmembrane Gi-coupled chemokine receptor whose cryo-EM structure (with three stabilizing cholesterol molecules) reveals a smaller helix VI conformational change upon CX3CL1 binding than other class A GPCRs; it supports both G protein-independent leukocyte adhesion (requiring the fractalkine chemokine-domain/mucin-stalk architecture) and G protein-dependent chemotaxis, promotes monocyte and NK cell survival via PI3K-AKT and ERK signaling (abrogated by the M280 loss-of-function polymorphism), drives microglial NRF2 signaling and restrains microglial aging, serves as a direct binding receptor for extracellular Tau (with phospho-S396 Tau showing reduced affinity), functions as an entry receptor for RSV in airway epithelium, and modulates β-cell insulin secretion through intracellular Ca²⁺ elevation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CX3CR1 is a seven-transmembrane G protein-coupled receptor for the chemokine fractalkine (CX3CL1) that couples leukocyte and microglial biology to chemotaxis, adhesion, and cell survival [#0]. It mediates two functionally separable outputs: pertussis toxin-independent leukocyte adhesion that requires the chemokine domain presented atop the fractalkine mucin stalk, and pertussis toxin-sensitive, G protein-dependent migration [#0]. Cryo-EM structures of the CX3CR1\\u2013Gi1 complex in ligand-free and CX3CL1-bound states show a comparatively small helix VI movement upon activation, stabilized by three bound cholesterol molecules essential for conformation and signal transduction [#16]. Downstream of CX3CL1, the receptor activates PI3K\\u2013AKT and ERK signaling to deliver pro-survival signals: it protects neurons from gp120 neurotoxicity through PI3K\\u2013Akt and NF-\\u03baB [#2], and sustains non-classical monocyte survival\\u2014a function abolished by the M280 loss-of-function variant, which impairs AKT/ERK activation without altering surface receptor levels [#7, #15]. In microglia, CX3CR1 supports NRF2 signaling, migration and phagocytosis and restrains a premature aging transcriptome [#11, #12], and it serves as a direct binding receptor for extracellular Tau\\u2014competing with CX3CL1 and driving microglial Tau internalization, with phospho-S396 Tau binding more weakly [#9]. Beyond immune and neural roles, CX3CR1 is expressed on pancreatic \\u03b2 cells where it potentiates glucose-stimulated insulin secretion via intracellular Ca\\u00b2\\u207a [#8], and functions as an entry/infection receptor for respiratory syncytial virus in airway epithelium in vitro and in vivo [#17, #18]. A CX3CR1 missense variant in Crohn's disease patients impairs Syk-dependent antifungal responses of mononuclear phagocytes [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established the receptor identity and the dual-output logic of fractalkine signaling, distinguishing G protein-independent adhesion from G protein-dependent migration.\",\n      \"evidence\": \"expression cloning with adhesion/migration assays and pertussis toxin inhibition across leukocytes including NK cells\",\n      \"pmids\": [\"9390561\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for how the chemokine/mucin architecture drives adhesion was not resolved\", \"In vivo relevance of the two outputs not addressed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Tested whether this orphan receptor (V28) could act as a viral co-receptor, broadening its functional range beyond chemotaxis.\",\n      \"evidence\": \"transient transfection of feline CCC cells supporting CD4-independent HIV-2 entry with sCD4\",\n      \"pmids\": [\"9143311\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single transfection/infection assay without binding-domain mapping\", \"No follow-up establishing physiological HIV co-receptor role\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified the downstream survival pathway by showing CX3CL1 engages PI3K-Akt and NF-\\u03baB to protect neurons.\",\n      \"evidence\": \"primary hippocampal neurons with antibody block, PI3K inhibition, and Akt/NF-\\u03baB readouts under gp120 neurotoxicity\",\n      \"pmids\": [\"10869418\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous neuronal CX3CR1 contribution in vivo not defined\", \"Link between Akt and NF-\\u03baB activation not mechanistically dissected\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined cytokine control of receptor abundance, showing TGF-\\u03b21 transcriptionally upregulates CX3CR1 in microglia via Smad elements.\",\n      \"evidence\": \"primary rat microglia with binding assays, ERK phosphorylation, mRNA stability, and promoter analysis\",\n      \"pmids\": [\"12446007\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct Smad occupancy of the promoter not demonstrated\", \"Functional consequence of blunted ERK signaling unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mapped the transcriptional architecture of CX3CR1 (three human promoters/exons) and established mouse-human divergence.\",\n      \"evidence\": \"genomic cloning, promoter-luciferase reporters, comparative genomics\",\n      \"pmids\": [\"12551893\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type-specific promoter usage not assigned\", \"Trans-acting factors for the regulatory elements not identified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed cytokine-specific regulation of NK-cell CX3CR1, with IL-15 suppressing and IL-2 increasing receptor expression and chemotactic function.\",\n      \"evidence\": \"primary mouse NK cells, in vivo IL-15 injection, RT-PCR, flow cytometry, chemotaxis assays\",\n      \"pmids\": [\"12881312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional mechanism of IL-15 suppression undefined\", \"Physiological context where IL-15 modulates NK trafficking not established\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Extended IL-15 regulation to human NK cells, linking surface receptor loss to diminished calcium flux and chemotaxis.\",\n      \"evidence\": \"human CD56+ NK cells, flow cytometry, calcium flux, and chemotaxis assays with CCR5/CXCR4 specificity controls\",\n      \"pmids\": [\"15598425\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism of selective receptor downregulation not resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established that CX3CR1 delivers a pro-survival signal to non-classical monocytes, with downstream consequences for atherogenesis.\",\n      \"evidence\": \"CX3CR1/CX3CL1 knockout mice, Bcl2 transgene rescue, in vitro survival assays, atherosclerosis model\",\n      \"pmids\": [\"18971423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediates linking receptor to survival not detailed here\", \"Whether survival is the sole atherogenic mechanism not excluded\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Generalized the survival function to DC and monocyte/macrophage development, distinguishing survival promotion from homing.\",\n      \"evidence\": \"competitive adoptive transfer with direct organ-injection controls and flow cytometry\",\n      \"pmids\": [\"21425158\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular survival pathway in precursors not defined\", \"Ligand source supporting precursor survival unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed a non-immune endocrine role, showing CX3CR1 potentiates \\u03b2-cell insulin secretion via intracellular Ca\\u00b2\\u207a.\",\n      \"evidence\": \"CX3CR1 KO mice, isolated mouse and human islet secretion assays, glucose tolerance tests, Ca\\u00b2\\u207a imaging, gene expression profiling\",\n      \"pmids\": [\"23582329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Coupling between Ca\\u00b2\\u207a elevation and secretory machinery not detailed\", \"G protein dependence of the islet effect not specified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified CX3CR1 as a direct extracellular Tau receptor mediating microglial Tau uptake, with phosphorylation modulating affinity.\",\n      \"evidence\": \"affinity chromatography, CX3CL1-Tau competition binding, microglial uptake assays, in vivo stereotaxic Tau clearance in KO mice\",\n      \"pmids\": [\"28810892\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tau binding site on the receptor not mapped\", \"Whether Tau triggers canonical signaling or only internalization unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Tied a human loss-of-function variant (M280) to defective monocyte survival via impaired AKT/ERK, with surface expression preserved.\",\n      \"evidence\": \"primary monocytes from genotyped human donors, serum-starvation survival assays, AKT/ERK Western blots, flow cytometry\",\n      \"pmids\": [\"29415879\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How M280 selectively impairs G protein/kinase coupling not structurally defined\", \"Disease consequences of impaired survival not directly tested here\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked CX3CR1 to vascular disease through macrophage polarization, showing deficiency protects against hypoxic pulmonary hypertension.\",\n      \"evidence\": \"CX3CR1-/- mice in hypoxic PH model with macrophage polarization, conditioned-media SMC proliferation, and pharmacological inhibition\",\n      \"pmids\": [\"28125278\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor signaling driving polarization not isolated\", \"CX3CL1 source in the lung niche not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected CX3CR1 to microglial homeostasis by showing it sustains NRF2 signaling, migration, and phagocytosis.\",\n      \"evidence\": \"primary Cx3cr1-/- microglia, RT-PCR for Nrf2 targets, migration/phagocytosis assays, in vivo sulforaphane in a tauopathy model\",\n      \"pmids\": [\"30769286\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link from receptor to NRF2 induction unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed CX3CR1 normally restrains a premature microglial aging transcriptome without major chromatin remodeling.\",\n      \"evidence\": \"RNA-seq and ATAC-seq of Cx3cr1-/- vs WT microglia with morphological analysis\",\n      \"pmids\": [\"31792059\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptional regulators downstream of CX3CR1 not identified\", \"Functional consequence of the aging signature in vivo not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified CX3CR1 as an RSV receptor in human pediatric airway epithelium.\",\n      \"evidence\": \"in situ hybridization, IHC, and CX3CR1-blocking with viral load readout in primary differentiated airway cultures\",\n      \"pmids\": [\"31726465\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor-virus binding interface not mapped in this study\", \"Antibody blocking alone without genetic confirmation\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Confirmed CX3CR1 as an RSV receptor in vivo and defined the G-protein CX3CR1 binding site as required for infection.\",\n      \"evidence\": \"recombinant RSV with G-protein mutations, antibody block, and morpholino knockdown of CX3CR1 in cotton rats\",\n      \"pmids\": [\"34037420\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Post-attachment entry steps mediated by CX3CR1 not defined\", \"Relevance to human in vivo infection not directly shown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided the structural mechanism of activation, showing a small helix VI shift stabilized by three cholesterol molecules.\",\n      \"evidence\": \"cryo-EM of CX3CR1-Gi1 in ligand-free and CX3CL1-bound states with functional validation\",\n      \"pmids\": [\"35767622\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of adhesion vs migration outputs not resolved\", \"How M280 or Tau binding alter the structure not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked a human CX3CR1 variant to impaired Syk-dependent antifungal immunity and colitis, establishing a Crohn's disease connection.\",\n      \"evidence\": \"CX3CR1+ MNP genetic ablation in mice, Syk inhibition, microbiome analysis, human genetic association with functional validation\",\n      \"pmids\": [\"29326275\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CX3CR1 signaling to Syk-coupled antifungal receptors not mapped\", \"Causal chain from receptor variant to fungal dysbiosis incompletely defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single receptor with a structurally subtle activation mechanism partitions among adhesion, chemotaxis, survival signaling, Tau/viral binding, and Ca\\u00b2\\u207a-coupled secretion across diverse cell types remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model linking ligand/cholesterol-stabilized conformation to divergent outputs\", \"Binding interfaces for non-chemokine ligands (Tau, RSV G protein) not structurally co-defined\", \"Cell-type-specific effector coupling not systematically mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 16]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [17, 18]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 16, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 16]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 10, 5]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CX3CL1\", \"GNAI1\", \"MAPT\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}